Pharmaceutical Strategy Could Save European ATMP Development
Better RWE Infrastructure And Pricing Models Also Key To European ATMP Sector
The European Commission’s Pharmaceutical Strategy should end regulatory “carve outs” like the hospital exemptions, and innovate pricing and reimbursement structures, says the Alliance for Regenerative Medicines.
